Nootropic agents, compositions of, and method of use thereof
申请人:Sanawa Kagaku Kenkyusho Company, Ltd.
公开号:US05434165A1
公开(公告)日:1995-07-18
An aromatic amino-substituted compound represented by formula: ##STR1## wherein A represents CH, N, or N.fwdarw.O; R.sub.1 represents a nitro group or an amino group; R.sub.2 represents a hydrogen atom, a lower alkyl group, or an acyl group; and R.sub.3 represents a group: ##STR2## wherein m represents 0 or 1; n represents an integer of from 0 to 3; R.sub.4 and R.sub.5 each represents a hydrogen atom or a lower alkyl group; R.sub.6 and R.sub.7 each represents a hydrogen atom or a straight chain or branched lower alkyl group; R.sub.4 and R.sub.6 may be joined together to form an alkylene chain forming a heterocyclic ring; R.sub.5 and R.sub.7 may be joined together to form an alkylene chain forming a heterocyclic ring and R.sub.6 and R.sub.7 may be joined together to form an alkylene chain forming a heterocyclic ring, or a pharmaceutically acceptable salt thereof, a process for producing the same, and a method for preventing or treating brain disfunction such as senile dementia or Alzheimer's disease by administering a nootropic agent containing the same as an active ingredient are disclosed.
synthesized a series of quinoline derivatives having a characteristic 1-azabicyclo[3.3.0]octane amine ring, and performed pharmacological evaluation of them. Acetylcholine esterase inhibitory activities of these derivatives were unexpectedly weak. Tests for central nervous muscariniccholinergicreceptorbinding affinity indicated that these compounds had higher affinities to muscarinic M1 receptors than to